European investors, including INKEF Capital and the Dementia Discovery Fund, have joined a large syndicate of other institutions to raise $42 million in Series A money for QurAlis Corp of Cambridge, US enabling it to progress new therapies in neurodegeneration. Besides INKEF and Dementia Discovery, the round was led by LS Polaris Innovation Fund and Mission BioCapital. QurAlis intends to use the funds to support development of therapies for amyotrophic lateral sclerosis (ALS) as well as the genetically related frontotemporal dementia.
